Skip to content

PolitiKit

Lobbying by Eli Lilly Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Eli Lilly Canada Inc.

Meetings this Parliament
0
With MPs
0
Since Nov 2021
0
Active registrations
1

Registrations in effect

Consultant In effect since Feb 13, 2026

Consultant Victor Neagu of Earnscliffe Strategies

Consultant lobbyists

  • Victor Neagu

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Great Lakes Pilotage Authority, Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Invest in Canada Hub, Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (10)
  • Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly's business.
  • The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
  • Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
  • Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
  • Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
  • C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
  • Free trade treaty agreement as it relates to the Canada/US Free Trade Agreement and free trade negotiations as it relates to Columbia, India, and the European Union.
  • Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
  • Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food & Drug Act.
  • Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.

Registration 962145-384784-1. Look it up in the official Registry

Reported meetings

No meetings reported since November 2021.

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.